- Home
- IMSR vs PALI Comparison
IMSR vs PALI Comparison
Compare IMSR & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMSR | PALI |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 240.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | IMSR | PALI |
|---|---|---|
| Price | $6.87 | $1.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 1.4M | ★ 2.8M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $5.95 | $0.55 |
| 52 Week High | $16.38 | $2.64 |
Technical Indicators
Market Signals| Indicator | IMSR | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 58.04 |
| Support Level | $5.98 | $1.57 |
| Resistance Level | $7.59 | $1.93 |
| Average True Range (ATR) | 0.57 | 0.12 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 54.11 | 91.97 |
Price Performance
Historical ComparisonAbout IMSR Terrestrial Energy Inc.
Terrestrial Energy Inc is an industry-leading technology company committed to delivering reliable, emission-free, and cost-competitive nuclear energy with a transformative advanced reactor, the Integral Molten Salt Reactor (IMSR). Its mission is to transform global energy markets by commercializing its IMSR Plant, which will deliver low-carbon electricity and industrial heat with superior economics, speed to deployment, and siting flexibility.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.